What are Vabysmo injections?
Vabysmo injections are a type of medication that is directly injected into the eye. They contain a drug called Vabysmo, also known as ranibizumab. This drug helps to block the growth of abnormal blood vessels in the eye, which is a characteristic of Wet AMD. By inhibiting the growth of these blood vessels, Vabysmo injections can help to slow down the progression of the disease and preserve vision.
How often are Vabysmo injections administered?
The frequency of Vabysmo injections for Wet AMD treatment can vary depending on various factors, including the severity of the disease and the individual patient's response to the treatment. In general, the initial phase of treatment involves more frequent injections. This is known as the loading phase. During the loading phase, Vabysmo injections are typically administered once a month for the first few months. This helps to quickly suppress the growth of abnormal blood vessels and stabilize the condition. After the loading phase, the frequency of injections may be reduced. Many patients transition to a maintenance phase, where injections are given less frequently. In some cases, patients may require ongoing monthly injections to maintain the desired treatment effect. However, other patients may be able to extend the time between injections. It is important to note that the specific treatment plan for Vabysmo injections will be determined by the individual's ophthalmologist based on their unique needs and response to the treatment.
What to expect during a Vabysmo injection
Before the injection, the eye will be numbed with anesthetic drops to minimize any potential discomfort. The injection itself is performed in a sterile environment, typically in the ophthalmologist's office. The ophthalmologist will use a small needle to inject the medication directly into the eye. The procedure is relatively quick and usually does not cause significant pain or discomfort. After the injection, patients may experience some mild redness or irritation at the injection site, but this typically resolves within a few days. It is important for patients to follow any post-injection instructions provided by their ophthalmologist, including the use of prescribed eye drops or medications. Regular follow-up appointments will also be scheduled to monitor the progress of the treatment.
Conclusion
Vabysmo injections are a common treatment option for Wet AMD. The frequency of these injections can vary depending on the individual patient's needs and response to the treatment. During the loading phase, injections are typically administered once a month, and the frequency may be reduced during the maintenance phase. It is important for patients to work closely with their ophthalmologist to develop a personalized treatment plan. Regular follow-up appointments are crucial for monitoring the progress of the treatment. Overall, Vabysmo injections can help to slow down the progression of Wet AMD and preserve vision.